View all IQVIA events


In today’s fast-changing regulatory environment, Real World Evidence (RWE) surrounding Safety, Comparative effectiveness and Outcomes have become a critical part of the Medical affairs and pre-commercialization strategy. As a result, we have noticed RWE being incorporated into shaping the clinical development strategy. However, when entering new markets or regions, it is important to recognize key challenges to generate fit-for-purpose evidence and learn how to overcome these barriers.
The session, tailored for the emerging biopharma, covers the following key objectives: